Cargando…
Using 2(nd) generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
Choices in medicine come with responsibility. With several TKI's (Tyrosine kinase inhibitors) available for front-line management of CML (Chronic Myeloid Leukemia), an astute clinician has to personalise, rationalise and take a pragmatic approach towards selection of the best drug for the ‘pati...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961879/ https://www.ncbi.nlm.nih.gov/pubmed/24665456 http://dx.doi.org/10.4103/2278-330X.126566 |